Seagen, A Wholly Owned Subsidiary Of Pfizer

This study tests a combination of two drugs, tucatinib and trastuzumab, in people with advanced solid tumors that have HER2 alterations. The goal is to see if the treatment can shrink or control the cancer. About 217 participants with various cancer types, including lung, uterine…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab and pertuzumab) can keep HER2-positive breast cancer from progressing longer than standard therapy alone. About 654 people with advanced or metastatic HER2+ breast cancer will take part. Neither p…

This study tests whether a combination of two drugs (disitamab vedotin and pembrolizumab) works better than standard chemotherapy for people with advanced bladder cancer that has spread. About 412 participants will be randomly assigned to receive either the new combo or chemo. Th…

This early-stage study tests a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. The main goal is to find a safe dose and understand side effects. About 41 participants will take…

This study tests whether adding tucatinib to standard T-DM1 therapy works better than T-DM1 alone for people with advanced HER2-positive breast cancer that has spread or cannot be removed surgically. About 466 participants will receive either tucatinib pills or a placebo twice da…

This early-stage study tests an experimental drug called SGN-MesoC2 in people with advanced solid tumors (cancers that have spread or can't be removed). The drug is designed to attach to cancer cells and kill them. The study aims to find the right dose and check safety in about 1…

This early-stage study tests a new drug, PF-08046052/SGN-EGFRd2, in people with advanced solid tumors that cannot be removed or have spread. The main goal is to check safety and side effects, and to find the right dose. About 68 participants with colorectal, lung, head and neck, …

This study is testing a new drug called tucatinib together with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and understand side effects. About 40 adults w…

This study tested a drug called tisotumab vedotin, alone or with other cancer medicines, in 350 people with advanced colorectal, lung, pancreatic, or head and neck cancers that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors and …

This early-stage trial tests a new drug, PF-08046044/SGN-35C, in 57 adults with advanced lymphomas (Hodgkin, T-cell, or B-cell types) who have run out of standard options. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Because this is …